Paper Details

  1. Home
  2. Paper Details

Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis.

Author: BeveridgeT, CurreyH L, DaviesJ, DixonA S, HarrisJ, MasonR M, Owen-SmithB, RobertsC J, VereD W, WoodlandJ

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study of patients with early rheumatoid arthritis compared the effectiveness of azathioprine, cyclophosphamide, and gold. All three drugs resulted in similar improvements in symptoms, reduced corticosteroid use, and slowed joint damage over 18 months. Azathioprine was the easiest to manage, while cyclophosphamide may have been slightly more effective but caused infertility in men. The study concluded that these anti-proliferative drugs offer a viable alternative to gold therapy for rheumatoid arthritis, potentially allowing for earlier treatment. However, long-term risks of these drugs need to be considered.
Paper Details　
Original Abstract of the Article :
Azathioprine, cyclophosphamide, and gold have been compared under double-blind conditions in the treatment of relatively early rheumatoid arthritis. Over 18 months the two "immunosuppressive" agents produced clinical improvement comparable to that achieved with gold, and they also facilitated a redu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/bmj.3.5934.763

データ提供：米国国立医学図書館（NLM）

Rheumatoid Arthritis Treatments: Comparing Azathioprine, Cyclophosphamide, and Gold

This study delves into the realm of rheumatoid arthritis (RA) treatments, comparing the effectiveness of azathioprine, cyclophosphamide, and gold therapy in patients with relatively early RA. The study involved a double-blind design to minimize bias and ensure a fair comparison of the three drugs. The results indicated that azathioprine and cyclophosphamide, both immunosuppressive agents, produced clinical improvement comparable to gold therapy.

Effective Treatment Options for Rheumatoid Arthritis

The study demonstrated that both azathioprine and cyclophosphamide effectively reduced corticosteroid dosage and retarded radiological joint deterioration, similar to gold therapy. The authors highlight the potential benefits of anti-proliferative agents as alternatives to gold therapy, especially in the early stages of RA. However, they also acknowledged the potential long-term hazards of these drugs, including malignancy and mutagenesis.

Managing Rheumatoid Arthritis: Balancing Benefits and Risks

Choosing the right treatment for RA involves carefully weighing the benefits and risks. While azathioprine, cyclophosphamide, and gold therapy offer potential benefits, they also carry potential risks. Understanding these risks and benefits is essential for making informed decisions about treatment. Think of it like navigating a desert – choosing the right path involves assessing the potential dangers and rewards.

Dr. Camel's Conclusion

This study provides valuable insights into the treatment of RA, comparing the effectiveness of three different drugs. The researchers’ findings highlight the importance of considering both short-term and long-term effects when choosing a treatment. Like a skilled desert explorer adapting their strategy to the changing landscape, clinicians must carefully select treatment options based on the specific needs and preferences of their patients with RA.
Date :
  1. Date Completed 1974-12-16
  2. Date Revised 2019-05-01
Further Info :

Pubmed ID

4606370

DOI: Digital Object Identifier

10.1136/bmj.3.5934.763

Related Literature

Article Analysis
・Effective treatment of arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.